Article

Swollen joints better predict ultrasound-defined inflammation in PsA than tender joints


 

Key clinical point: In patients with psoriatic arthritis (PsA), joint swelling was more closely related to and better predicted ultrasound-defined inflammation and active synovitis at 1 year than joint tenderness.

Major finding: Swollen joint count correlated better with greyscale and power Doppler (PD) joint scores (correlation coefficient [r] 0.37 and 0.47, respectively) than tender joint count (PD-joint score; r 0.33). Ultrasound verified active synovitis at 12-month follow-up was better predicted by swelling (odds ratio [OR] 6.33; 95% CI 3.70-10.83) vs. tenderness (OR 3.58; 95% CI 2.29-5.58) at baseline.

Study details: Findings are from a prospective study including 83 patients with PsA who underwent clinical and ultrasound examinations at 2 visits scheduled 12 months apart.

Disclosures: This work was funded by Pfizer. The authors declared no conflict of interests.

Source: Bosch P et al. Rheumatology. 2021;keab764 (Oct 21). Doi: 10.1093/rheumatology/keab764.

Recommended Reading

Predictors and risk factors for PsA transition in patients with psoriasis
Psoriatic Arthritis ICYMI
Effect of background methotrexate dose on tofacitinib efficacy in patients with PsA
Psoriatic Arthritis ICYMI
Higher odds for preterm, C-section births seen in women with PsA
Psoriatic Arthritis ICYMI
Clinical Edge Journal Scan Commentary: PsA November 2021
Psoriatic Arthritis ICYMI
Risankizumab outperforms placebo at 6 months for psoriatic arthritis
Psoriatic Arthritis ICYMI
Psoriatic arthritis and axial spondyloarthritis patients succeed with reduced TNF inhibitor dosing
Psoriatic Arthritis ICYMI
Tofacitinib postmarketing trial data shed light on JAK inhibitor risks
Psoriatic Arthritis ICYMI
Serious infection hospitalizations have declined in patients with PsA
Psoriatic Arthritis ICYMI
PsA: Long-term benefits of upadacitinib in patients with inadequate response to biologics
Psoriatic Arthritis ICYMI
Risk for serious infection lower in patients with PsA vs. RA treated with TNF inhibitors
Psoriatic Arthritis ICYMI